{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:08:12Z","timestamp":1792782492589,"version":"4.5.0"},"reference-count":39,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,4,22]],"date-time":"2015-04-22T00:00:00Z","timestamp":1429660800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2015,4,22]],"date-time":"2015-04-22T00:00:00Z","timestamp":1429660800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100001545","name":"Children's Tumor Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001545","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NTAP","id":[{"id":"https:\/\/ror.org\/01359dk79","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Blood Cancer"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1002\/pbc.25546","type":"journal-article","created":{"date-parts":[[2015,4,22]],"date-time":"2015-04-22T09:45:02Z","timestamp":1429695902000},"page":"1709-1716","source":"Crossref","is-referenced-by-count":73,"title":["Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of neurofibromatosis type 1"],"prefix":"10.1002","volume":"62","author":[{"given":"Edwin","family":"Jousma","sequence":"first","affiliation":[{"name":"Division of Experimental Hematology and Cancer Biology; Children's Hospital Medical Center; Cincinnati Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilat A.","family":"Rizvi","sequence":"additional","affiliation":[{"name":"Division of Experimental Hematology and Cancer Biology; Children's Hospital Medical Center; Cincinnati Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqiang","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Experimental Hematology and Cancer Biology; Children's Hospital Medical Center; Cincinnati Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Janhofer","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch; National Cancer Institute; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Dombi","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch; National Cancer Institute; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Dunn","sequence":"additional","affiliation":[{"name":"Division of Imaging Resource Center; Children's Hospital Medical Center; Cincinnati Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-Ok","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pediatrics; Biostatistics and Epidemiology; Cincinnati Children's Hospital Medical Center; Cincinnati Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea R.","family":"Masters","sequence":"additional","affiliation":[{"name":"Simon Cancer Center; Indiana University School of Medicine; Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Medicine; Division of Clinical Pharmacology; Indiana University School of Medicine; Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Cripe","sequence":"additional","affiliation":[{"name":"Center for Childhood Cancer and Blood Diseases; Nationwide Children's Hospital; Columbus Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Ratner","sequence":"additional","affiliation":[{"name":"Division of Experimental Hematology and Cancer Biology; Children's Hospital Medical Center; Cincinnati Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,4,22]]},"reference":[{"key":"10.1002\/pbc.25546-BIB0001|pbc25546-cit-0001","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1136\/jmg.26.11.712","article-title":"A genetic study of von Recklinghausen neurofibromatosis in south east Wales. II. Guidelines for genetic counselling","volume":"26","author":"Huson","year":"1989","journal-title":"J Med Genet"},{"key":"10.1002\/pbc.25546-BIB0002|pbc25546-cit-0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/GIM.0b013e3181bf15e3","article-title":"Clinical and genetic aspects of neurofibromatosis 1","volume":"12","author":"Jett","year":"2010","journal-title":"Genet Med"},{"key":"10.1002\/pbc.25546-BIB0003|pbc25546-cit-0003","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/1098-1004(200006)15:6<541::AID-HUMU6>3.0.CO;2-N","article-title":"Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects","volume":"15","author":"Messiaen","year":"2000","journal-title":"Hum Mutat"},{"key":"10.1002\/pbc.25546-BIB0004|pbc25546-cit-0004","first-page":"23","article-title":"GTPase activating proteins: Critical regulators of intracellular signaling","volume":"1602","author":"Donovan","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"10.1002\/pbc.25546-BIB0005|pbc25546-cit-0005","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/hmg\/ddl016","article-title":"Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients","volume":"15","author":"Maertens","year":"2006","journal-title":"Hum Mol Genet"},{"key":"10.1002\/pbc.25546-BIB0006|pbc25546-cit-0006","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/(SICI)1096-8628(19970516)70:2<138::AID-AJMG7>3.0.CO;2-U","article-title":"Type 1 neurofibromatosis: A descriptive analysis of the disorder in 1,728 patients","volume":"70","author":"Friedman","year":"1997","journal-title":"Am J Med Genet."},{"key":"10.1002\/pbc.25546-BIB0007|pbc25546-cit-0007","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/978-3-642-32864-0_15","volume-title":"Neurofibromatosis Type 1","author":"Upadhyaya","year":"2012"},{"key":"10.1002\/pbc.25546-BIB0008|pbc25546-cit-0008","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jpeds.2011.08.051","article-title":"Pediatric plexiform neurofibromas: Impact on morbidity and mortality in neurofibromatosis type 1","volume":"160","author":"Prada","year":"2012","journal-title":"J Pediatr"},{"key":"10.1002\/pbc.25546-BIB0009|pbc25546-cit-0009","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/gcc.20921","article-title":"Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors","volume":"50","author":"Beert","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1002\/pbc.25546-BIB0010|pbc25546-cit-0010","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1212\/01.wnl.0000435744.57038.af","article-title":"Recommendations for imaging tumor response in neurofibromatosis clinical trials","volume":"81","author":"Dombi","year":"2013","journal-title":"Neurology"},{"key":"10.1002\/pbc.25546-BIB0011|pbc25546-cit-0011","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1212\/WNL.0b013e318207b031","article-title":"Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas","volume":"76","author":"Jakacki","year":"2011","journal-title":"Neurology"},{"key":"10.1002\/pbc.25546-BIB0012|pbc25546-cit-0012","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S1470-2045(12)70414-X","article-title":"Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: A phase 2 trial","volume":"13","author":"Robertson","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1002\/pbc.25546-BIB0013|pbc25546-cit-0013","first-page":"982","article-title":"Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: A neurofibromatosis clinical trials consortium phase II study","volume":"61","author":"Weiss","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1002\/pbc.25546-BIB0014|pbc25546-cit-0014","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/pbc.23015","article-title":"Preclincial testing of sorafenib and RAD001 in the Nf(flox\/flox); DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging","volume":"58","author":"Wu","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.25546-BIB0015|pbc25546-cit-0015","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.cell.2008.08.041","article-title":"Nf1-dependent tumors require a microenvironment containing Nf1+\/\u2212- and c-kit-dependent bone marrow","volume":"135","author":"Yang","year":"2008","journal-title":"Cell"},{"key":"10.1002\/pbc.25546-BIB0016|pbc25546-cit-0016","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.brainresbull.2011.08.005","article-title":"Genetically engineered mouse models shed new light on the pathogenesis of neurofibromatosis type I-related neoplasms of the peripheral nervous system","volume":"88","author":"Brossier","year":"2012","journal-title":"Brain Res Bull"},{"key":"10.1002\/pbc.25546-BIB0017|pbc25546-cit-0017","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00401-012-1056-7","article-title":"Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition","volume":"125","author":"Prada","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.1002\/pbc.25546-BIB0018|pbc25546-cit-0018","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ccr.2007.12.027","article-title":"Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells","volume":"13","author":"Wu","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1002\/pbc.25546-BIB0019|pbc25546-cit-0019","article-title":"MEK inhibition exhibits efficacy in human and mouse Neurofibromatosis tumors, despite transcriptional feedback onto ERK","author":"Jessen","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1002\/pbc.25546-BIB0020|pbc25546-cit-0020","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1038\/sj.onc.1210261","article-title":"Tumor microenvironment and neurofibromatosis type I: Connecting the GAPs","volume":"26","author":"Le","year":"2007","journal-title":"Oncogene"},{"key":"10.1002\/pbc.25546-BIB0021|pbc25546-cit-0021","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0959-437X(95)90053-5","article-title":"Ras signaling and NF1","volume":"5","author":"McCormick","year":"1995","journal-title":"Curr Opin Gen Devel"},{"key":"10.1002\/pbc.25546-BIB0022|pbc25546-cit-0022","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1158\/1078-0432.CCR-09-1920","article-title":"A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer","volume":"16","author":"Haura","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1002\/pbc.25546-BIB0023|pbc25546-cit-0023","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/1078-0432.CCR-09-1883","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK\/ERK kinase inhibitor PD-0325901 in patients with advanced cancers","volume":"16","author":"LoRusso","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1002\/pbc.25546-BIB0024|pbc25546-cit-0024","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nrc1503","article-title":"Targeting the mitogen-activated protein kinase cascade to treat cancer","volume":"4","author":"Sebolt-Leopold","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1002\/pbc.25546-BIB0025|pbc25546-cit-0025","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/BJ20070797","article-title":"The selectivity of protein kinase inhibitors: A further update","volume":"408","author":"Bain","year":"2007","journal-title":"Biochem J"},{"key":"10.1002\/pbc.25546-BIB0026|pbc25546-cit-0026","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00280-011-1620-1","article-title":"Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer","volume":"68","author":"Boasberg","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1002\/pbc.25546-BIB0027|pbc25546-cit-0027","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1172\/JCI60578","article-title":"MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors","volume":"123","author":"Jessen","year":"2013","journal-title":"Journal Clin Invest"},{"key":"10.1002\/pbc.25546-BIB0028|pbc25546-cit-0028","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1017\/S1740925X08000021","article-title":"Mast cells can contribute to axon-glial dissociation and fibrosis in peripheral nerve","volume":"3","author":"Monk","year":"2007","journal-title":"Neuron Glia Biol"},{"key":"10.1002\/pbc.25546-BIB0029|pbc25546-cit-0029","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1089\/jop.2009.0060","article-title":"PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion","volume":"25","author":"Huang","year":"2009","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1002\/pbc.25546-BIB0030|pbc25546-cit-0030","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/2159-8290.CD-12-0313","article-title":"Elucidating distinct roles for NF1 in melanomagenesis","volume":"3","author":"Maertens","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1002\/pbc.25546-BIB0031|pbc25546-cit-0031","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1158\/0008-5472.CAN-12-0334","article-title":"Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency","volume":"72","author":"See","year":"2012","journal-title":"Cancer Res"},{"key":"10.1002\/pbc.25546-BIB0032|pbc25546-cit-0032","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1750-1172-7-75","article-title":"Growth dynamics of plexiform neurofibromas: A retrospective cohort study of 201 patients with neurofibromatosis 1","volume":"7","author":"Nguyen","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1002\/pbc.25546-BIB0033|pbc25546-cit-0033","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1212\/01.wnl.0000250332.89420.e6","article-title":"NF1 plexiform neurofibroma growth rate by volumetric MRI: Relationship to age and body weight","volume":"68","author":"Dombi","year":"2007","journal-title":"Neurology"},{"key":"10.1002\/pbc.25546-BIB0034|pbc25546-cit-0034","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e3181bd1326","article-title":"Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas","volume":"73","author":"Kim","year":"2009","journal-title":"Neurology"},{"key":"10.1002\/pbc.25546-BIB0035|pbc25546-cit-0035","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nature09454","article-title":"Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma","volume":"467","author":"Bollag","year":"2010","journal-title":"Nature"},{"key":"10.1002\/pbc.25546-BIB0036|pbc25546-cit-0036","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.molcel.2012.11.002","article-title":"Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals","volume":"49","author":"Albeck","year":"2013","journal-title":"Mol Cell"},{"key":"10.1002\/pbc.25546-BIB0037|pbc25546-cit-0037","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1172\/JCI63193","article-title":"Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice","volume":"123","author":"Chang","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1002\/pbc.25546-BIB0038|pbc25546-cit-0038","unstructured":"Widemann BCML Fisher MJ Weiss BD Kim A Dombi E Baldwin A Whitcomb P Martin S Gillespie A Doyle A"},{"key":"10.1002\/pbc.25546-BIB0039|pbc25546-cit-0039","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/ng.2650","article-title":"A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer","volume":"45","author":"Lunardi","year":"2013","journal-title":"Nature Genet"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.25546","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.25546","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/pbc.25546\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T06:54:25Z","timestamp":1625381665000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.25546"}},"subtitle":["MEK Inhibition in Neurofibroma"],"short-title":[],"issued":{"date-parts":[[2015,4,22]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"URL":"https:\/\/doi.org\/10.1002\/pbc.25546","archive":["Portico"],"relation":{},"ISSN":["1545-5009"],"issn-type":[{"value":"1545-5009","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4,22]]}}}